Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Vera Therapeutics, Inc.NASDAQ: VERA
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $132K rose 10.9% year over year, behind the +89.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 5.7% from the prior quarter.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +10.9% toward the trailing-twelve-month pace of +89.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 468K USD
- Year-over-year change
- +345.7%
- 4-year CAGR
- +27.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 468K | +345.7% |
| FY2024 | 2024-12-31 | 105K | +400.0% |
| FY2023 | 2023-12-31 | 21K | +102.5% |
| FY2022 | 2022-12-31 | (846K) | -580.7% |
| FY2021 | 2021-12-31 | 176K | — |
Depreciation & Amortization vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's LTM Jun 2026 depreciation & amortization of $536K is the 8th highest of the 10 companies compared; the peer median is $2.43M.
- Its year-over-year change of +89.4% is the highest of 10, against a peer median of -9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.75M | -9.8% | -6.6% | 3.2% | |
| LTM Jun 2026 | $10.67M | +22.9% | +92.7% | — | |
| LTM Mar 2026 | $3.08M | +50.1% | +151.3% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.65M | -20.7% | +140.9% | 35.9% |
| LTM Mar 2026 | $2.43M | +1.2% | +1.2% | 1.0% | |
| LTM Jun 2026 | $2.25M | -58.5% | +71.0% | 0.5% | |
| LTM Mar 2026 | $1.65M | -13.9% | +19.6% | — | |
| LTM Jun 2026 | $536K | +89.4% | — | — | |
| LTM Mar 2026 | $528K | +7.3% | -17.1% | 6.3% | |
| LTM Jun 2026 | $379K | -11.0% | +42.8% | 19.9% | |
| Peer median (excluding VERA) | $2.43M | -9.8% | +42.8% | 4.7% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | (846K) | 0 | 0 | 0 |
| Gross Profit | 0 | 846K | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.48M | 69.84M | 78.23M | 126.17M | 215.26M |
| Selling, General & Admin | 11.92M | 21.91M | 23.79M | 41M | 100.22M |
| Operating Expenses | 34.4M | 91.75M | 102.01M | 167.17M | 315.47M |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| EBITDA | (32.41M) | (88.91M) | (92.18M) | (144.42M) | (291.62M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (34.4M) | (90.9M) | (102.01M) | (167.17M) | (315.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15K | 1.75M | 7.98M | 20.71M | 24.48M |
| Interest Expense | 20K | 992K | 3.79M | 7.63M | 7.53M |
| Other Income / Expenses | 1.79M | 1.85M | 6.02M | 15.02M | 15.86M |
| Income Before Tax | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K | 1K |
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| EPS (Diluted) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| Weighted Avg Shares | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Weighted Avg Shares (Diluted) | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.